Abstract: The present invention relates to an inclusion compound of fumagillol derivative or its salt with hydroxypropyl-?-cyclodextrin or sulfobutylether-7-?-cyclodextrin, and pharmaceutical compositions comprising the same. The inclusion compound according to the present invention has superior water solubility and stability while exhibiting low toxicity, rendering it valuable as an anticancer agent or inhibitor of tumor metastasis.

Abstract: In an aspect, a composite anode active material including: a porous particles, said porous particles including: a plurality of composite nanostructures; and a first carbonaceous material binding the composite nanostructures, wherein the porous particles have pores within the particle, and wherein the composite nanostructures include a crystalline second carbonaceous material substrate including at least one carbon nano-sheet, and a plurality of metal nanowires arranged at intervals on the crystalline second carbonaceous material substrate is disclosed.

Abstract: Provided is a lithium battery including: a positive electrode, a negative electrode, and an organic electrolytic solution, wherein the negative electrode has a metal/metalloid nanostructure, and the organic electrolytic solution includes a lithium sulfonimide-based compound.

Abstract: A composite anode active material, an anode and a lithium battery each including the composite anode active material, and a method of preparing the composite anode active material. The composite anode active material includes a composite core, and a coating layer covering at least a region of the composite core, wherein the composite core includes a carbonaceous substrate and a metal/semi-metal nanostructure on the carbonaceous substrate, the coating layer is more predominant on the nanostructure than on the carbonaceous substrate, and the coating layer includes a metal oxide.

Abstract: In an aspect, a composite anode active material including a composite core; and a coating layer covering at least a region of the composite core, wherein the composite core comprises a carbonaceous substrate; and a nanostructure disposed on the substrate, and the coating layer includes a metal oxide; an anode and a lithium battery each including the composite anode active material; and a method of preparing the composite anode active material are provided.

Abstract: Disclosed is a negative electrode for a rechargeable lithium battery that includes a current collector and a negative active material layer on the current collector, the negative active material layer having an active mass density in a range of about 1.6 g/cc to about 2.1 g/cc and including graphite and a pore-forming agent.

Abstract: A negative active material and a lithium battery including the negative active material. The negative active material includes primary particles, each including: a crystalline carbonaceous core having a surface on which silicon-based nanowires are disposed; and an amorphous carbonaceous coating layer that is coated on the crystalline carbonaceous core so as not to expose at least a portion of the silicon-based nanowires. Due to the inclusion of the primary particles, an expansion ratio is controlled and conductivity is provided and thus, a formed lithium battery including the negative active material may have improved charge-discharge efficiency and cycle lifespan characteristics.

Abstract: A negative active material and a lithium battery including the same are disclosed. Due to the inclusion of silicon nanowires formed on a spherical carbonaceous base material, the negative active material may increase the capacity and cycle lifespan characteristics of the lithium battery.

Abstract: Disclosed herein is an anticancer composition, comprising obovatol, represented by the following Chemical Formula 1, obovatal, represented by the following Chemical Formula 2, and/or pharmaceutical salts thereof. The composition exhibits the activity of inhibiting the growth of cancer cells and suppressing the expression and activity of matrix metalloproteinases (MMPs), and thus can be useful for the prophylaxis and treatment of cancer as well as for the inhibition of cancer metastasis.

Abstract: The present invention relates to an inclusion compound of fumagillol derivative or its salt with hydroxypropyl-?-cyclodextrin or sulfobutylether-7-?-cyclodextrin, and pharmaceutical compositions comprising the same. The inclusion compound according to the present invention has superior water solubility and stability while exhibiting low toxicity, rendering it valuable as an anticancer agent or inhibitor of tumor metastasis.

Abstract: Disclosed herein are novel obovatol derivatives represented by Chemical Formula 1, and pharmaceutically acceptable salts thereof. Having the ability to inhibit the growth of cancer cells and induce apoptosis in cancer cells, the derivatives or pharmaceutically acceptable salts thereof are useful in the prevention and treatment of cancer and in the suppression of cancer metastasis. Also, a method for preparing the derivatives, and pharmaceutical compositions comprising the derivatives as active ingredients are disclosed. wherein R1, R2 and R3 are as defined in the specification.

Abstract: The present invention relates to an inclusion compound of fumagillol derivative or its salt with hydroxypropyl-?-cyclodextrin or sulfobutylether-7-?-cyclodextrin, and pharmaceutical compositions comprising the same. The inclusion compound according to the present invention has superior water solubility and stability while exhibiting low toxicity, rendering it valuable as an anticancer agent or inhibitor of tumor metastasis.

Abstract: A liquid crystal display includes a liquid crystal panel having a color filter including a red filter, a transparent filter, and a blue filter, and a backlight panel at a rear of the liquid crystal panel. The backlight panel includes electron emission regions and a phosphor layer that emits light when excited by electrons emitted from the electron emission regions. The phosphor layer includes a first phosphor layer having a red phosphor and a blue phosphor, and a second phosphor layer having a green phosphor. The backlight panel is configured to emit light from the first phosphor layer and the second phosphor layer sequentially.

Abstract: The present invention relates to an inclusion compound of fumagillol derivative or its salt with hydroxypropyl-?-cyclodextrin or sulfobutylether-7-?-cyclodextrin, and pharmaceutical compositions comprising the same. The inclusion compound according to the present invention has superior water solubility and stability while exhibiting low toxicity, rendering it valuable as an anticancer agent or inhibitor of tumor metastasis.

Abstract: An electron emission display includes first and second substrates facing each other, a plurality of election emission regions provided on the first substrate, a black layer formed on a first surface of the second substrate between the phosphor layers, and an anode electrode coupled to the phosphor and black layers. The anode electrode has a light transmissivity ranging from about 3% to about 15%. A method of forming the anode electrode includes forming an interlayer on the phosphor and black layer, depositing a conductive material on the second substrate, and removing the interlayer through a firing process.

Abstract: An electron emission device and a method of manufacturing the same. The electron emission device of the present invention includes at least one anode formed on one side of a substrate, and a light emitter including a plurality of multiple divided phosphor layers formed on the anode at predetermined intervals. At least one of the phosphor layers has at least one partition pattern. The phosphor layer structure of the present invention is capable of maintaining superior color coordinate characteristics and greatly improving luminance characteristics.

Abstract: An electron emission display including a first substrate having at least one electron emission device and a second substrate opposite the first substrate. The second substrate is formed with an effective region and a non-effective region. The effective region includes a fluorescent layer for emitting light by collision with electrons emitted from the electron emission device. The non-effective region includes a region in which a light-shielding layer has a transparent conductive layer and a metal layer. The transparent conductive layer is formed in the effective region where the fluorescent layer is absent. The second substrate improves the brightness of light emitted from the fluorescent layer and prevents a power supply layer, to which a high voltage is applied, from being damaged, because the transparent conductive layer is not formed under the effective region.

Abstract: Disclosed herein are novel obovatol derivatives represented by Chemical Formula 1, and pharmaceutically acceptable salts thereof. Having the ability to inhibit the growth of cancer cells and induce apoptosis in cancer cells, the derivatives or pharmaceutically acceptable salts thereof are useful in the prevention and treatment of cancer and in the suppression of cancer metastasis. Also, a method for preparing the derivatives, and pharmaceutical compositions comprising the derivatives as active ingredients are disclosed. wherein R1,R2 and R3 are as defined in the specification.

Abstract: An electron emission display includes first and second substrates that face each other, a plurality of electron emission elements that are arrayed on the first substrate, phosphor and black layers that are formed on a surface of the second substrate, and an anode electrode that is formed of metal and located on surfaces of the phosphor and black layers. The anode electrode is formed to satisfy the following condition: 0.3 ?m?A?3 ?m where, A indicates a distance between the anode electrode and the phosphor layer.

Abstract: An electron emission display includes first and second substrates facing each other, a plurality of driving electrodes formed on the first substrate, a plurality of electron emission regions controlled by the driving electrodes, a focusing electrode disposed on and insulated from the driving electrodes and provided with openings through which electron beams pass, a plurality of phosphor layers formed on a surface of the second substrate, an anode electrode formed on surfaces of the phosphor layers, and a plurality of spacers for maintaining a gap between the first and second substrates. Among the electron emission regions disposed in the opening adjacent to the spacer, one electron emission region, which is closest to the adjacent spacer, is spaced apart from an inner wall of the opening by a first distance that is different from a second distance from another electron emission region, which is farthest from the adjacent spacer, to the inner wall of the opening.